» Articles » PMID: 29989524

Brain Irradiation and Gadobutrol Administration in Pediatric Patients with Brain Tumors: Effect on MRI Brain Signal Intensity

Overview
Journal Radiology
Specialty Radiology
Date 2018 Jul 11
PMID 29989524
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose To determine whether treatment affects MRI signal intensity in pediatric patients with primary brain tumors independent of the administration of macrocyclic gadolinium-based contrast agents (GBCAs). Materials and Methods This retrospective, single-center study included 78 patients (mean age, 7.7 years ± 5.4) with primary brain tumors who underwent macrocyclic GBCA-enhanced MRI from 2015 to 2018. Three groups were compared: (a) patients who had undergone radiation therapy (37 patients, 26 of whom had undergone concurrent chemotherapy), (b) patients who had undergone chemotherapy only (17 patients), and (c) patients who had received no treatment ("no-treatment group," 24 patients). The signal intensity in the globus pallidus (GP), thalamus, dentate nucleus (DN), and pons was measured on unenhanced T1-weighted images. GP-to-thalamus and DN-to-pons signal intensity ratios were compared among groups with analysis of variance by using the Kruskal-Wallis test, followed by post hoc pairwise tests with Tukey adjustment, and were analyzed relative to group, total cumulative doses of GBCA, age, and sex with multivariable linear models. Results The mean number of GBCA-enhanced MRI examinations in the radiation therapy, chemotherapy-only, and no-treatment groups was 7.11, 7.29, and 4.96, respectively (P < .01 for the radiation therapy and chemotherapy groups compared with the no-treatment group). The DN-to-pons ratio in the radiation therapy group was higher than that in both the no-treatment group and the chemotherapy-only group (P < .01 for both). There was no significant difference in the DN-to-pons ratios between the chemotherapy-only group and the no-treatment group (P = .99). The GP-to-thalamus ratios did not differ among all three groups (P = .09). There was no dose-dependent effect of GBCA on the DN-to-pons and GP-to-thalamus ratios when adjusting for the effects of treatment (P = .21 and P = .38, respectively). Conclusion Brain irradiation contributes to a higher dentate nucleus signal intensity in pediatric patients with brain tumor independent of the administration of macrocyclic gadolinium-based contrast agents. © RSNA, 2018.

Citing Articles

Gadolinium Contrast Agent Deposition in Children.

Ouyang M, Bao L J Magn Reson Imaging. 2024; 61(1):70-82.

PMID: 38597340 PMC: 11645493. DOI: 10.1002/jmri.29389.


Biocompatible and bioactivable terpolymer-lipid-MnO Nanoparticle-based MRI contrast agent for improving tumor detection and delineation.

Yen T, Abbasi A, He C, Lip H, Park E, Amini M Mater Today Bio. 2024; 25:100954.

PMID: 38304342 PMC: 10832465. DOI: 10.1016/j.mtbio.2024.100954.


Evaluation of the effect of multiple administrations of gadopentetate dimeglumine or gadoterate meglumine on brain T1-weighted hyperintensity in pediatric patients.

Towbin A, Zhang B, Dillman J Pediatr Radiol. 2021; 51(13):2568-2580.

PMID: 34286351 DOI: 10.1007/s00247-021-05134-4.


Assessment of gadolinium deposition in the brain tissue of pediatric and adult congenital heart disease patients after contrast enhanced cardiovascular magnetic resonance.

Zaki N, Parra D, Wells Q, Chew J, George-Durrett K, Pruthi S J Cardiovasc Magn Reson. 2020; 22(1):82.

PMID: 33267835 PMC: 7713146. DOI: 10.1186/s12968-020-00676-2.


Impact of brain tumors and radiotherapy on the presence of gadolinium in the brain after repeated administration of gadolinium-based contrast agents: an experimental study in rats.

Jost G, Frenzel T, Boyken J, Pietsch H Neuroradiology. 2019; 61(11):1273-1280.

PMID: 31297571 PMC: 6817760. DOI: 10.1007/s00234-019-02256-3.